A Pbmcs From Cll Patients N 16 Were Incubated For 24 H With Medium

PBMCs from seven untreated CLL patients were incubated with medium ...
PBMCs from seven untreated CLL patients were incubated with medium ...
PBMCs from seven untreated CLL patients were incubated with medium ...
PBMCs from seven untreated CLL patients were incubated with medium ...
PBMCs from CLL patients were cultured with CK2 inhibitors and viability ...
PBMCs from CLL patients were cultured with CK2 inhibitors and viability ...
CLL cultures with Pic and R406. (A) PBMCs from six CLL patients were ...
CLL cultures with Pic and R406. (A) PBMCs from six CLL patients were ...
PBMCs from different CLL patients were cultured in vitro for 48 hours ...
PBMCs from different CLL patients were cultured in vitro for 48 hours ...
Phenotypic analysis of PBMCs from patients with CLL 24 hours after ...
Phenotypic analysis of PBMCs from patients with CLL 24 hours after ...
Depletion of autologous B cells in vitro from PBMCs of CLL patients ...
Depletion of autologous B cells in vitro from PBMCs of CLL patients ...
Morphology of the cells. PBMCs were incubated for 24 h in presence of ...
Morphology of the cells. PBMCs were incubated for 24 h in presence of ...
(A) PBMCs from a healthy donor or a CLL patient were stimulated with or ...
(A) PBMCs from a healthy donor or a CLL patient were stimulated with or ...
Morphology of the cells. PBMCs were incubated for 24 h in presence of ...
Morphology of the cells. PBMCs were incubated for 24 h in presence of ...
OSU03012 is cytotoxic toward CLL cells in vitro. PBMCs from 11 patients ...
OSU03012 is cytotoxic toward CLL cells in vitro. PBMCs from 11 patients ...
A. Resting PBMCs (n = 5) were incubated in medium for up to 7 days ...
A. Resting PBMCs (n = 5) were incubated in medium for up to 7 days ...
ILT2 is overexpressed on T cells from CLL patients. (A) PBMCs were ...
ILT2 is overexpressed on T cells from CLL patients. (A) PBMCs were ...
a Chemonaïve CLL patients were treated with fludarabine and ...
a Chemonaïve CLL patients were treated with fludarabine and ...
Cell surface markers showing differential expression. CLL PBMCs were ...
Cell surface markers showing differential expression. CLL PBMCs were ...
B cells are sensitive to Lurbinectedin. a CLL PBMC were incubated with ...
B cells are sensitive to Lurbinectedin. a CLL PBMC were incubated with ...
PBMC were incubated for 24 hours with increasing concentrations of ...
PBMC were incubated for 24 hours with increasing concentrations of ...
Human PBMCs were incubated with β-glu6 (100 μg/mL) (lower panels) or ...
Human PBMCs were incubated with β-glu6 (100 μg/mL) (lower panels) or ...
PBMC samples from CLL patients (>90% CD5+CD19+ as determined by FACS ...
PBMC samples from CLL patients (>90% CD5+CD19+ as determined by FACS ...
Human PBMCs were incubated with increasing concentration of CA in the ...
Human PBMCs were incubated with increasing concentration of CA in the ...
PBMC of 20 CLL patients (gray squares) and of 24 healthy donors (white ...
PBMC of 20 CLL patients (gray squares) and of 24 healthy donors (white ...
A, PBMCs (1.5×106/mL) were cultured for 16 h with various... | Download ...
A, PBMCs (1.5×106/mL) were cultured for 16 h with various... | Download ...
PBMC samples from CLL patients (>90% CD5+CD19+ as determined by FACS ...
PBMC samples from CLL patients (>90% CD5+CD19+ as determined by FACS ...
Experimental setups and datasets from in-vitro CLL patient PBMC ...
Experimental setups and datasets from in-vitro CLL patient PBMC ...
Antp-LP4 peptide specifically induces CLL cancer cell death. PBMCs ...
Antp-LP4 peptide specifically induces CLL cancer cell death. PBMCs ...
A) Peripheral blood mononuclear cells (PBMC) from healthy donors or CLL ...
A) Peripheral blood mononuclear cells (PBMC) from healthy donors or CLL ...
CLL PBMCs contain increased numbers of MDSCs and MDSC subsets A ...
CLL PBMCs contain increased numbers of MDSCs and MDSC subsets A ...
Inhibition of autophagy decreases primary CLL cell viability. (a) PBMCs ...
Inhibition of autophagy decreases primary CLL cell viability. (a) PBMCs ...
Expression of costimulatory molecules on PBMCs from patient 021 with ...
Expression of costimulatory molecules on PBMCs from patient 021 with ...
Cytotoxic impact of cannabinoids on CLL primary cells. PBMC from CLL ...
Cytotoxic impact of cannabinoids on CLL primary cells. PBMC from CLL ...
Cell extract from the incubation of PBMCs for 6 h with unlabeled ...
Cell extract from the incubation of PBMCs for 6 h with unlabeled ...
Cell viability of PBMCs incubated in the absence (positive control) and ...
Cell viability of PBMCs incubated in the absence (positive control) and ...
(A) Human PBMCs (105 cells/well) were treated with 20 µg/ml oenothein B ...
(A) Human PBMCs (105 cells/well) were treated with 20 µg/ml oenothein B ...
Pro-inflammatory cytokine release from CLL patients' PBMC after ...
Pro-inflammatory cytokine release from CLL patients' PBMC after ...
A) Whole PBMC were incubated overnight in the presence (black bars) or ...
A) Whole PBMC were incubated overnight in the presence (black bars) or ...
Freshly isolated human PBMCs were pre-incubated for 1 hour at 37°C in ...
Freshly isolated human PBMCs were pre-incubated for 1 hour at 37°C in ...

Loading image details...

Source
Dimensions